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ABSTRACT: Cholinergic denervation has been
associated with falls and slower gait speed and b-amyloid
deposition with greater severity of axial motor impairments
in Parkinson disease (PD). However, little is known about
the association between the presence of extra-nigral path-
ological conditions and freezing of gait (FoG). Patients
with PD (n5 143; age, 65.567.4 years, Hoehn and Yahr
stage, 2.46 0.6; Montreal Cognitive Assessment score,
25.962.6) underwent [11C]methyl-4-piperidinyl propio-
nate acetylcholinesterase and [11C]dihydrotetrabenazine
dopaminergic PET imaging, and clinical, including FoG,
assessment in the dopaminergic “off” state. A subset of
subjects (n561) underwent [11C]Pittsburgh compound-B
b-amyloid positron emission tomography (PET) imaging.
Normative data were used to dichotomize abnormal b-
amyloid uptake or cholinergic deficits. Freezing of gait
was present in 20 patients (14.0%). Freezers had longer
duration of disease (P5 0.009), more severe motor dis-
ease (P<0.0001), and lower striatal dopaminergic activity
(P5 0.013) compared with non-freezers. Freezing of gait
was more common in patients with diminished neocortical
cholinergic innervation (23.9%, v255.56, P5 0.018), but
not in the thalamic cholinergic denervation group (17.4%,
v25 0.26, P5 0.61). Subgroup analysis showed higher
frequency of FoG with increased neocortical b-amyloid
deposition (30.4%, Fisher Exact test: P5 0.032). Fre-
quency of FoG was lowest with absence of both patholog-
ical conditions (4.8%), intermediate in subjects with single
extra-nigral pathological condition (14.3%), and highest
with combined neocortical cholinopathy and amyloidop-
athy (41.7%; Cochran-Armitage trend test, Z5 2.63,
P5 0.015). Within the group of freezers, 90% had at least
one of the two extra-nigral pathological conditions stud-
ied. Extra-nigral pathological conditions, in particular the
combined presence of cortical cholinopathy and amyloid-
opathy, are common in PD with FoG and may contribute
to its pathophysiology.VC 2014 International Parkinson and
Movement Disorder Society
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Advancing Parkinson’s disease (PD) is associated with
disabling axial motor complications, such as freezing of
gait (FoG), with diminishing responsiveness to dopami-
nergic medications.1,2 Nigrostriatal dopaminergic dener-
vation secondary to a-synuclein related pathology is the
defining pathological feature of most early-stage PD clin-
ical manifestations.3 Heterogeneous involvement of
other projection systems and other pathological condi-
tions variably exacerbate the effects of nigrostriatal
denervation and is a significant contributor to the varied
clinical features of advancing PD. Unlike the uniform
presence of striatal dopaminergic denervation in
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clinically manifest PD, for example, significant heteroge-
neity is seen in the range of cholinergic denervation seen
in nondemented PD patients.4 Neocortical cholinergic
denervation is present only in approximately one third of
nondemented PD patients when compared with normal
control subjects.4 Comorbid b-amyloid plaques also are
variably present in PD.5
We previously identified pedunculopontine nucleus
(PPN)-thalamic and forebrain cortical cholinergic pro-
jection system degeneration as a prominent factor
related to falls and gait slowing in PD, respectively.6,7
We recently found also that cortical b-amyloid deposi-
tion is associated with severity of postural instability
and gait difficulties features in PD.8
We set out to further refine these observations and
test the hypothesis that extra-nigral changes of sub-
cortical or neocortical cholinergic denervation (cholin-
opathy) and increased b-amyloid deposition
(amyloidopathy) are factors associating specifically
with FoG in PD.
Subjects and Methods
Subjects and Clinical Test Battery
This cross-sectional study involved 143 subjects
with PD (106 men and 37 women); mean age,
65.56 7.4 (range, 50-84) years. The PD subjects met
the UK Parkinson’s Disease Society Brain Bank clinical
diagnostic criteria.9 Fifty PD subjects were taking a
combination of dopamine agonist and carbidopa-
levodopa medications, 67 were using carbidopa-
levodopa alone, 15 were taking dopamine agonists
alone, and 11 were not receiving dopaminergic drugs.
No subjects were treated with anti-cholinergic or cho-
linesterase inhibitor drugs. Most subjects had moder-
ate severity of disease: 4 patients in stage 1, 7 in stage
1.5, 35 in stage 2, 63 in stage 2.5, 30 in stage 3, 3 in
stage 4, and 1 in stage 5 of the modified Hoehn and
Yahr classification.10 Mean duration of disease was
6.064.3 (SD; range, 0.5-20) years. The mean motor
examination score on the Movement Disorder Society
Revised Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS) was 32.56 14.2 (range, 8-72). Subjects
receiving dopaminergic medications were examined in
the morning after dopaminergic medications had been
withheld overnight. The presence or absence of FoG
was based on clinical examination and directly
observed by the clinician examiner based on a non-
zero score on item 3.11, “Freezing of Gait,” of the
MDS-UPDRS motor examination.11 For most reliable
assessment, FoG classification should be based on
objective confirmation by an experienced observer
during clinical assessment rather than on patient recol-
lection.12 Details of gait speed, UPDRS motor, and
cognitive testing from this cohort of patients are
reported elsewhere.4,8,13 All PD subjects previously
reported in the quantitative studies by Petrou et al.13
(n540) and Muller et al.8 (n544) are included in the
expanded dataset.8,13
Each patient underwent neuropsychological examina-
tion as described previously.4 Global cognitive compos-
ite z-scores were calculated based on normative data.
Patients also completed a Montreal Cognitive Assess-
ment, with a mean score of 25.962.6 (range, 15-30).14
This study was approved by the Institutional Review
Board of the University of Michigan School of Medi-
cine. Written informed consent was obtained from all
subjects.
Imaging Techniques
All subjects underwent brain magnetic resonance
imaging (MRI) and methyl-4-piperidinyl propionate
(PMP) acetylcholinesterase and [11C]dihydrotetrabena-
zine (DTBZ) vesicular monoamine transporter type 2
(VMAT2) positron emission tomography (PET),
except for one subject for whom the DTBZ PET scan
failed because of technical reasons. All DTBZ PET
scans showed evidence of nigrostriatal degeneration. A
subset of PD subjects (n561) who were clinically
identified as being at increased risk for development of
dementia based on older age, subjective cognitive com-
plaints, and more severe motor disease also underwent
[11C]Pittsburgh compound B (PIB) b-amyloid PET
imaging.
[11C]dihydrotetrabenazine PET imaging was per-
formed the morning after withholding dopaminergic
medications overnight. The MRI was performed on a
3 Tesla Philips Achieva system (Philips, Best, The
Netherlands), and PET imaging was performed in 3D
imaging mode with an ECAT Exact HR1 tomograph
(Siemens Molecular Imaging, Inc., Knoxville, TN) as
previously reported.4
The [11C]DTBZ, [11C]PMP, and [11C]PIB were pre-
pared as described previously.15,16 Dynamic PET scan-
ning was performed for 70 minutes using a bolus dose
of 15 mCi [11C]PMP dose. Bolus/infusion protocols
were used for [11C]DTBZ (15 mCi) in 60 minutes and
for [11C]PIB (18 mCi) in 70 minutes.17
Analysis
All image frames were spatially coregistered within
subjects with a rigid-body transformation to reduce
the effects of subject motion during the imaging ses-
sion.18 Interactive Data Language image analysis soft-
ware (Research Systems, Inc., Boulder, CO) was used
to manually trace volumes of interest on MRI images
to include the thalamus, caudate nucleus, and puta-
men of each hemisphere. Total neocortical volumes of
interest were defined using semi-automated threshold
delineation of the cortical gray matter signal on the
MRI scan4.
[11C]dihydrotetrabenazine distribution volume ratios
were estimated using the Logan plot graphical analysis
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method with the striatal time activity curves as the
input function and the total neocortex as reference tis-
sue, a reference region overall low in VMAT2 binding
sites, with the assumption that the nondisplaceable dis-
tribution is uniform across the brain at equilibrium.19
Acetylcholinesterase [11C]PMP hydrolysis rates (k3)
were estimated using the striatal volume of interest
(defined by manual tracing on the MRI scan of the
putamen and caudate nucleus) as the tissue reference
for the integral of the precursor delivery.20 There are
two major brain cholinergic projection systems: the
basal forebrain complex, providing the principal cho-
linergic input to the cortical mantle, and the PPN
complex, providing cholinergic inputs to the thalamus,
cerebellum, basal ganglia, other brainstem nuclei, and
the spinal cord.21 Both degenerate variably in PD.
Acetylcholinesterase PET imaging assesses cholinergic
terminal integrity with cortical uptake, reflecting
largely basal forebrain neuron integrity, and thalamic
uptake, principally reflecting PPN integrity.
[11C]PIB PET data were analyzed using the Logan
graphical method and the cerebellum as reference
regions.22,23 Global cortical PIB distribution volume
ratio was calculated.
To determine the frequency of each of the two
extra-nigral pathological conditions, we used norma-
tive data to dichotomize abnormal uptake or deficits.
We classified acetylcholinesterase PET scans as either
below or within normal range because of the significant
overlap of cholinergic innervation seen between sub-
jects with PD and healthy controls. Abnormal neocorti-
cal and thalamic cholinergic innervation was based on a
5th percentile cutoff from non-PD elderly normative
data (n529; mean age, 66.86 10.9 years; comparable
to the current patient cohort).4
We used [11C]PIB b-amyloid data from young to
middle-aged healthy subjects (n5 115 men/6 women),
mean age 46.76 3.4 (range, 40-50 years) to define ele-
vated [11C]PIB binding in the patients, because signifi-
cant fibrillary b-amyloid deposition occurs in many
cognitive normal elderly individuals.24 The maximum
normal neocortical [11C]PIB distribution volume ratio
was 1.17, and PD patients with values exceeding this
threshold were defined as exhibiting increased b-
amyloid binding.
Standard pooled-variance t or Satterthwaite’s method
of approximate t tests (tapprox) were used for group
comparisons. Chi-squared testing was performed for
comparison of proportions between groups and with
Fisher’s exact test in the presence of small cell popula-
tions. The Cochran-Armitage trend test was performed
to determine a dose–response relationship when assess-
ing the association between no, single, or dual extra-
nigral pathological conditions and FoG status. In the
subset of subjects who had completed all three PET
measures, multiple logistic regression was performed,
using FoG status as the outcome parameter, and cholin-
opathy, amyloidopathy, striatal VMAT2 bindings as
PET regressors and clinical confounder variables
(motor, cognitive performance, and duration of disease)
that were shown to be different between freezers and
non-freezers. Analyses were performed using SAS ver-
sion 9.2, SAS Institute, Cary, NC, USA).
Results
Patients With FoG
Twenty subjects had observed FoG (14.0%). Freezers
had longer duration of disease, more severe motor
impairments, and lower striatal dopaminergic activity
compared with non-freezers (Table 1). No significant dif-
ferences were seen in age or sex distribution between
groups. Freezers manifested a trend toward lower cogni-
tive performance compared with non-freezers (Table 1).
Cholinergic PET Findings in Freezers
Neocortical cholinergic denervation was heterogene-
ous, with 46 PD patients (32.2%) exhibiting neocorti-
cal acetylcholinesterase activity below normal-range
activity levels. Below-normal-range PPN-thalamic ace-
tylcholinesterase activity levels were seen in 23
TABLE 1. Mean (6SD) values of demographic, clinical, cognitive and striatal [11C]dihydrotetrabenazine VMAT2 distribution
volume ratios in the patients with PD without versus with FoGa
PD Without FoG (n5 123) PD With FoG (n5 20) Statistical Significance
Age 65.46 7.7 66.46 6.0 t5 0.58; p5 0.56
Sex (females/males) 34/89 3/17 v25 1.43; p5 0.23
Duration of motor disease(y) 5.66 4.1 8.36 4.7 t5 2.65; p5 0.009
Hoehn and Yahr stage 2.46 0.5 3.06 0.7 tapprox5 5.23; p< 0.0001
Motor MDS-UPDRS 30.36 12.9 46.76 14.0 t5 5.21; p< 0.0001
Montreal Cognitive Assessment 26.06 2.6 25.36 2.7 t5 1.18; p5 0.24
Global cognitive composite z-score 20.346 0.87 20.756 1.06 t5 1.92; p5 0.058
Striatal VMAT2 binding 1.966 0.27 1.816 0.27 t5 2.53, p5 0.013
aGender distribution is presented as proportions. Levels of statistical difference between groups are also presented.
Note: tapprox5Satterthwaite’s method of approximate t tests.
Abbreviations: VMAT2, vesicular monoamine transporter type 2; MDS-UPDRS, Movement Disorder Society Revised Unified Parkinson’s Disease Rating Scale.
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patients (16.1%). A significantly higher proportion of
FoG subjects were in the below-normal range com-
pared with the normal-range neocortical acetylcholin-
esterase group: 23.9% versus 9.3% (v25 5.56, P5
0.018, Fig. 1A). There was no significant difference in
the proportion of freezers in the below-normal range
versus normal-range PPN-thalamic acetylcholinesterase
group: 17.4% versus 13.3% (v25 0.26, P50.61;
Fig. 1B).
Subgroup Analysis of b-Amyloid PET Findings
in Freezers
A subset of PD subjects (n561) underwent also
[11C]PIB b-amyloid PET imaging. Subjects in this sub-
group were older (69.06 6.3 vs 62.967.1), had more
severe cognitive impairments (composite z-score
20.876 0.96 vs 20.0460.68) and slightly higher
Hoehn and Yahr stage (2.760.5 vs 2.360.6) com-
pared with the remainder of the subjects (n582).
However, no significant difference was seen in the fre-
quency of FoG between these two subgroups (16.4%
vs 12.2% (v250.51, P5 0.44). Increased neocortical
b-amyloid accumulation was present in 23 of the 61
subjects (37.7%) who completed the [11C]PIB scan. A
significantly higher proportion of patients with FoG
were in the “positive” compared with the “negative”
neocortical b-amyloid group: 30.4% versus 7.9%
(Fisher’s exact test: P50.032; Fig. 1C).
Proportion of Freezers in Subgroup
Combinations of Patients With Cortical
Amyloidopathy or Cholinopathy
No significant association was found between the
presence of cortical cholinopathy and amyloidopathy
(v25 0.32, P5 0.58); 47.8% of subjects with amyloid-
opathy have normal-range neocortical cholinergic
innervation, and 52.2% have below-normal-range
activity. Combined pathological conditions were pres-
ent in 19.7% of patients, absence of both in 34.4%,
with the remainder exhibiting either isolated cholinop-
athy (27.9%) or amyloidopathy (18%).
FoG frequency was lowest in subjects with
absence of both pathological conditions (4.8%),
intermediate in subjects with single extra-nigral path-
ological condition (14.3%), and highest with com-
bined neocortical cholinopathy and amyloidopathy
(41.7%; Fisher’s exact test: P5 0.03). A significant
trend was seen indicating a dose–response associa-
tion between absence and presence of single and
dual extra-nigral pathological conditions (Cochran-
Armitage trend test Z5 2.63, P5 0.015; Fig. 2).
Within the group of freezers, 90% of all freezers
had at least one of the two extra-nigral pathological
conditions studied. Figure 3 illustrates low-range
cortical acetylcholinesterase and “positive”
b-amyloid imaging findings in PD freezer compared
with the non-freezer.
FIG. 1. Proportion of patients (%) with FoG in normal range versus below-range cortical (A), and PPN-thalamic cholinergic activity (B). FoG was
more common in patients with diminished neocortical cholinergic innervation but not in the thalamic cholinergic denervation group. Subgroup analy-
sis of patients who completed b-amyloid PET showed higher frequency of FoG in patients with positive compared with negative neocortical b-
amyloid deposition (C). Note: *Statistical significant group difference, P< 0.05. AChE, acetylcholinesterase; FoG, freezing of gait; PPN, pedunculo-
pontine nucleus; PET, positron emission tomography.
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Multiple logistic regression analysis was performed
to evaluate the relative effects of neocortical amyloid-
opathy versus cholinopathy while controlling for
effects of potentially confounding variables, including
striatal VMAT2 binding, estimated duration of motor
disease, MDS-UPDRS motor score, and composite
cognitive z-score (Table 2). No significant difference
in age was found between freezers (69.266.7) and
non-freezers (68.06 4.1; t50.56, P50.58) in this
subgroup. An overall significant model (v25 17.66;
P5 0.0072) was seen with neocortical amyloidopathy
as the only significant predictor variable, whereas
neocortical cholinopathy was no longer significant.
Nigrostriatal dopaminergic denervation had borderline
significance in the model (P50.057).
A post hoc analysis was performed to evaluate the
prediction of FoG status based on absolute neocortical
b-amyloid [11C]PIB distribution volume ratio rather
than as a binary classification variables. Results of the
multivariate logistic regression analysis (total model
v25 17.26; P5 0.0084), using the absolute neocortical
b-amyloid [11C]PIB distribution volume ratio as a pre-
dictor variable, confirmed the binary amyloidopathy
parameter findings (v253.85; P50.049).
Discussion
Freezing of gait is a debilitating feature of PD, with
poorly defined pathophysiological mechanisms. Sud-
den freezing may be related to altered neocortical reg-
ulation of movement, perhaps exacerbated by
progressive impairment of subcortical locomotor cen-
ters function.25 Several studies explored the sources of
altered cerebral functions associated with FoG. These
studies show evidence of disruption of cortical func-
tion, including neocortical networks involved in execu-
tive functions and sensorimotor perception in subjects
who tend to have severe nigrostriatal denervation, par-
ticularly of the caudate nucleus.25-27 A recent resting
state functional MRI brain connectivity study identi-
fied reduced cortical network connectivity in PD with
FoG, consistent with a role for cortical dysfunction in
FoG.27 Localization of the key nodes within the loco-
motor network whose dysfunction is responsible for
FoG remains unclear. Recent studies emphasize altered
interactions between subcortical, in particular the
PPN, and cortical regions. For example, one recent
functional MRI study of PD subjects with known FoG
during a virtual reality timed “up and go” gait task
provides evidence of dysfunction across coordinated
neural networks, including the caudate nucleus, globus
pallidus pars interna, thalamus, and mesencephalic
locomotor center.28 A recent diffusion tensor imaging
study showed evidence of reduced connectivity of the
PPN and cortical regions.29 Similarly, a PPN deep
brain stimulation study showed significant regional
cerebral blood flow increments not only to subcortical
but also to cortical regions, including the sensorimotor
and supplemental motor cortices.30
The main findings in this study reflect an association
between presence of observed FoG and extra-nigral
pathological conditions. However, mechanistic or etio-
pathogenetic inferences cannot be drawn from these
observations. Furthermore, our PET markers may
indicate the presence of a cortical pathological condi-
tion but cannot explain the episodic nature of the FoG
movement disorder. In this respect, our findings may
identify a weak link within a neural circuit, where
freezing behavior in PD may occur because of
FIG. 2. Proportion of freezers (%) in subgroups of patients with
absence, single, or combined presence of cortical amyloidopathy or
cholinopathy. A significant trend effect was seen, with FoG frequency
being lowest with absence of both pathological condition, intermediate
in subjects with single extra-nigral pathological condition, and highest
with combined neocortical cholinopathy and amyloidopathy (Cochran-
Armitage trend test, Z52.63; P5 0.015). *Statistical significance of
trend, P< 0.05. FoG, freezing of gait.
FIG. 3. AChE (upper row) and b-amyloid imaging (lower row) findings
in PD non-freezer (left) and freezer (right). Images illustrate reduced
cortical cholinergic activity and increased b-amyloid deposition in the
freezer compared with the non-freezer. AChE, acetylcholinesterase;
PD, Parkinson’s disease. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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impaired communication between complementary yet
competing neural networks.31,32
Our findings support the role of neocortical changes
in PD patients with FoG. We found that the effects of
cholinergic projection system deficits associated with
FoG were driven by neocortical denervation but not
by PPN-thalamic degeneration. Degeneration of cho-
linergic PPN-thalamic projections is associated with
postural reflex impairments, whose underlying patho-
physiology may differ from that leading to FoG.33,34
However, PPN-thalamic and forebrain cortical cholin-
ergic denervation do partially overlap,4 and a potential
role of PPN-thalamic cholinergic denervation cannot
be excluded.
We recently reported a relationship between pos-
tural instability and gait difficulty feature severity and
neocortical b-amyloid burden in PD patients at risk
for development of dementia.8 Similar findings have
been reported for lower cerebrospinal fluid b-amyloid
concentrations in patients with PD and the postural
instability and gait difficulty motor phenotype.35
These associations of cerebrospinal fluid b-amyloid
concentrations with severity of postural instability,
gait difficulty, and lower limb bradykinesia were also
independent from age and cognitive functions in PD
patients, and no association between cerebrospinal
fluid markers and other motor features were found.35
Findings of lack of significant cholinergic status pre-
dictor of FoG in the multivariate model limited to the
subgroup of 61 patients who completed all three PET
scans should be considered as preliminary, given the
smaller sample size and because concurrent presence of
amyloidopathy and cholinopathy showed a significant
dose–response effect in a trend analysis comparing FoG
status relative to absence or presence of one or two of
these extra-nigral pathological conditions The prelimi-
nary multivariate logistic regression analysis in the sub-
set of 61 subjects who completed all three PET scans
identified amyloidopathy as a predictor of FoG inde-
pendent of the degree of cognitive impairment and
other clinical confounder variables. Although the extra-
nigral pathological conditions of cortical cholinopathy
and amyloidopathy are common in subjects with
FoG, they are not exclusively present in FoG: other
pathological conditions or mechanisms also may play a
role. These preliminary observations need to be con-
firmed in future prospective studies with semiquantita-
tive assessment of FoG, using dedicated provocation
protocols,12 preferably performed in both the dopami-
nergic medication “on” and “off” states.
We found that freezers had more severe nigrostriatal
denervation compared with non-freezers in our study,
and nigrostriatal denervation had borderline signifi-
cant prediction of FoG in the multifactorial model.
This is in keeping with the fact that FoG can respond
to dopaminergic medications in some subjects,36 such
as in patients with less severe disease. These findings
emphasize multi-system changes underlying FoG in
PD, which is supported by our findings of a dose–
response relationship between the higher frequency of
FoG in subjects with combined extra-nigral pathologi-
cal conditions, compared with a single presence or
absence of both. Relatively isolated impairment of a
single system in PD (i.e., nigrostriatal denervation)
may not lead to the development of some motor
impairments because of adaptive plasticity in the
remaining intact systems. The degree of dopamine
responsiveness of gait freezing may depend on the
integrity and adaptive plasticity of the remainder of
the neural networks supporting mobility functions.
A limitation of our study is that assessment of FoG
was based on an unprovoked protocol with no special
maneuvers such as walking through narrow passages
or making turns. This may limit the sensitivity of our
FoG assessment and may explain the relatively low
frequency of FoG in our study population. This low
sensitivity also may result in a relative underestimation
of effect size estimates. A relative advantage is the
high specificity of FoG classification. Patients on cho-
linesterase inhibitors were not eligible for this study
because we were performing acetylcholinesterase PET
imaging. This exclusion criterion resulted in a predom-
inantly nondemented cohort and may provide an alter-
native explanation for the relatively low frequency of
FoG in our study. Another limitation of the study is
that the subset of 61 PD subjects who underwent all
three PET scans were older, had greater cognitive
impairments, and had slightly higher Hoehn and Yahr
TABLE 2. Results of multiple logistic regression analysis and FoG in PD patientsa
Variable Logit Regression Coefficient Standard Error v2; p Value
Cortical acetylcholinesterase group status (below versus normal range) 0.31 0.48 0.41; p5 0.52
Cortical b-amyloid status(positive versus negative) 0.95 0.48 3.97; p5 0.046
Striatal VMAT2 distribution volume ratio 26.40 3.36 3.63; p5 0.057
Duration of motor disease 20.05 0.09 0.28; p5 0.59
Motor MDS-UPDRS score 0.05 0.03 2.23; p5 0.14
Global cognitive composite z-score 0.48 0.55 0.76; p5 0.38
aOverall model was significant (v25 17.66; P5 0.0072).
Abbreviations: VMAT2, vesicular monoamine transporter type 2; MDS-UPDRS, Movement Disorder Society Revised Unified Parkinson’s Disease Rating Scale.
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stages compared with the remainder of the subjects.
However, no significant difference in the frequency of
FoG was found between these two subgroups. Further-
more, despite the fact that all subjects in this subgroup
had more significant cognitive impairment, the fre-
quency of amyloidopathy in subjects with FoG was
nearly fourfold higher compared with the non-FoG at-
risk subjects. We conclude that cortical cholinopathy
and amyloidopathy are common extra-nigral patho-
logical conditions in PD with FoG and in the presence
of more severe nigrostriatal degeneration may contrib-
ute to its pathophysiology.
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